[1]. Association of PPI and antibiotics with the clinical outcomes of HCC patients receiving atezolizumab and bevacizumab: A multicenter analysis.
Hepatology research : the official journal of the Japan Society of Hepatology (2023年) [査読] 有
[DOI] [2]. Breach of tolerance versus burden of bile acids: Resolving the conundrum in the immunopathogenesis and natural history of primary biliary cholangitis.
Journal of autoimmunity [巻]136 [頁]103027 (2023年) [査読] 有
[DOI] [3]. Diagnostic accuracy of enhanced liver fibrosis test for nonalcoholic steatohepatitis-related fibrosis: Multicenter study.
Hepatology research : the official journal of the Japan Society of Hepatology [巻]53 [号]4 [頁]312 -321 (2023年) [査読] 有
[DOI] [4]. Survival outcomes from atezolizumab plus bevacizumab versus Lenvatinib in Child Pugh B unresectable hepatocellular carcinoma patients.
Journal of cancer research and clinical oncology (2023年) [査読] 有
[DOI] [5]. Rifaximin Improves Liver Functional Reserve by Regulating Systemic Inflammation.
Journal of clinical medicine [巻]12 [号]6 (2023年) [査読] 有
[DOI]